Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

细胞毒性T细胞 抗原 T细胞 CD8型 生物 T细胞受体 免疫疗法 癌症研究 嵌合抗原受体 细胞 免疫学 分子生物学 免疫系统 体外 生物化学 遗传学
作者
Paul Maciocia,Patrycja Wawrzyniecka,Brian Philip,Ida Ricciardelli,Ayse U. Akarca,Shimobi Onuoha,David K. Cole,Andrew K. Sewell,Karl S. Peggs,David C. Linch,Teresa Marafioti,Martin Pulè
出处
期刊:Blood [Elsevier BV]
卷期号:128 (22): 811-811
标识
DOI:10.1182/blood.v128.22.811.811
摘要

Abstract T-cell lymphomas and leukemias are aggressive, treatment-resistant cancers with poor prognosis. Immunotherapeutic approaches have been limited by a lack of target antigens discriminating malignant from healthy T-cells. While treatment of B-cell cancers has been enhanced by targeting pan B-cell antigens, an equivalent approach is not possible for T-cell malignancies since profound T-cell depletion, unlike B-cell depletion, would be prohibitively toxic. We propose an immunotherapeutic strategy for targeting a pan T-cell antigen without causing severe depletion of normal T-cells. The α/β T-cell receptor (TCR) is a pan T-cell antigen, expressed on >90% of T-cell lymphomas and all normal T-cells. An overlooked feature of the TCR is that the β-constant region comprises 2 functionally identical genes: TRBC1 and TRBC2. Each T-cell expresses only one of these. Hence, normal T-cells will be a mixture of individual cells expressing either TRBC1 or 2, while a clonal T-cell cancer will express TRBC1 or 2 in its entirety. Despite almost identical amino acid sequences, we identified an antibody with unique TRBC1 specificity. Flow cytometry (FACS) of T-cells in normal donors (n = 27) and patients with T-cell cancers (n = 18) revealed all subjects had TRBC1 and 2 cells in both CD4 and CD8 compartments, with median TRBC1 expression of 35% (range 25-47%). In addition, we examined viral-specific T-cells in healthy volunteers, by generation of Epstein Barr virus-specific primary cytotoxic T-cell lines (3 donors) or by identification of cytomegalovirus-specific (3 donors) or adenovirus-specific (5 donors) T-cells by peptide stimulation. We demonstrated similar TRBC1: 2 ratios in viral-specific cells, suggesting that depletion of either subset would not remove viral immunity. Next, using FACS and immunohistochemistry, we showed that TCR+ cell lines (n = 8) and primary T-cell lymphomas and leukemias (n = 55) across a wide range of histological subtypes were entirely restricted to one compartment (34% TRBC1). As proof of concept for TRBC-selective therapy, we developed anti-TRBC1 chimeric antigen receptor (CAR) T-cells. After retroviral transduction of healthy donor T-cells, comprising mixed TRBC1/2 populations, 90% of T-cells expressed CAR on the cell surface. No detectable TRBC1 T-cells remained in the culture, suggesting selective depletion of this population. Anti-TRBC1 CAR T-cells secreted interferon-γ in response to TRBC1-expressing target cell lines (p<0.001) or autologous normal TRBC1+ cells (p<0.001), and not TRBC2 cell lines or autologous normal TRBC2 cells. Anti-TRBC1 CAR killed multiple TRBC1 cell lines (p<0.001) and autologous normal TRBC1 cells (p<0.001), and not TRBC2 cell lines or autologous normal TRBC2 cells. These cell-line based findings were confirmed using primary cells from two patients with TRBC1+ adult T-cell leukaemia/lymphoma. We demonstrated specific tumour kill by allogeneic or autologous T-cells in vitro, despite partial downregulation of surface TCR by tumour cells. We developed a xenograft murine model of disseminated T-cell leukemia by engrafting engineered firefly luciferase+ TRBC1+ Jurkat cells in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Bioluminescent imaging and FACS of marrow at 5 days following IV T-cell injection showed that while mice treated with untransduced T-cells progressed, mice receving anti-TRBC1 CAR T-cells had disease clearance (p<0.0001). In a further model, mice were engrafted with equal proportions of TRBC1-Jurkat and TRBC2-Jurkat cells. FACS analysis of bone marrow at 5 days following T-cell injection demonstrated specific eradication of TRBC1 and not TRBC2 tumour by anti-TRBC1 CAR (p<0.001). In summary, we have demonstrated a novel approach to investigation and targeting of T-cell malignancies by distinguishing between two possible TCR β-chain constant regions. Using CART-cells targeting TRBC1 we have demonstrated proof of concept for anti-TRBC immunotherapy. Unlike non-selective approaches targeting the entire T-cell population, TRBC targeting could eradicate a T-cell tumour while preserving sufficient normal T-cells to maintain cellular immunity. Disclosures Maciocia: Autolus: Equity Ownership, Patents & Royalties: TRBC1 and 2 Targeting for the Diagnosis and Treatment of T-cell Malignancies. Philip:Autolus: Equity Ownership. Onuoha:Autolus: Employment, Equity Ownership. Pule:Amgen: Honoraria; Roche: Honoraria; UCL Business: Patents & Royalties; Autolus Ltd: Employment, Equity Ownership, Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国的应助被zzz采纳,获得10
1秒前
勤奋一一的应助被yy采纳,获得10
2秒前
ppp发布了新的文献求助10
2秒前
2秒前
caleb发布了新的文献求助10
3秒前
酷波er的应助被fushy27采纳,获得10
3秒前
cc发布了新的文献求助20
3秒前
4秒前
4秒前
season发布了新的文献求助10
4秒前
ccc发布了新的文献求助10
4秒前
4秒前
英勇的鹰发布了新的文献求助10
4秒前
郭书磊完成签到,获得积分10
4秒前
4秒前
领导范儿的应助被辞忧采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
5秒前
深深设完成签到,获得积分10
6秒前
7秒前
Ava的应助被niudayun采纳,获得30
8秒前
传奇3的应助被Ysci采纳,获得10
8秒前
Owen的应助被12581采纳,获得10
9秒前
知了发布了新的文献求助10
9秒前
MZ发布了新的文献求助10
9秒前
008关注了科研通微信公众号
9秒前
郭书磊发布了新的文献求助10
9秒前
洋芋发布了新的文献求助10
9秒前
10秒前
yj发布了新的文献求助10
10秒前
年轻的晓亦完成签到,获得积分20
10秒前
10秒前
11秒前
科研通AI6.2的应助被152455采纳,获得10
11秒前
科研通AI6.4的应助被152455采纳,获得10
11秒前
科研通AI6.4的应助被152455采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171039
求助须知:如何正确求助?哪些是违规求助? 9563751
关于积分的说明 21772122
捐赠科研通 7762548
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554676
邀请新用户注册赠送积分活动 2475657